Chemomab Therapeutics (CMMB) Precio de Acción, Cotización, Noticias e Historial | Benzinga

Chemomab Therapeutics Ltd (CMMB) Precio de Acción, Cotización, Noticias e Historial

CMMBNASDAQ

Trade with Public

Trade with Public

$1.18

-0.085-6.72%

Últ. Act.: Oct 19, 1:16 PM

$1.28

0.0151.19%

Panorámica generalNoticias Previsión de beneficios Eventos Precios objetivo Finanzas Sentimiento Propiedad Comparar Informe de acciones

© 2026 Benzinga | All Rights Reserved

Estadísticas Clave

Apertura

$1.25

Cierre

-

Volumen / Prom.

17.65K / 103.44K

Rango diario

$1.19 - $1.26

Rango de 52 semanas

1.05 - 3.50

Capitalización bursátil

$8.65M

Ratio PER

-

Rentabilidad por dividendo

-

Exchange

NASDAQ

RSI

28

Interés en corto

0.15%

Días para cubrir

1

Noticias Recientes de Chemomab Therapeutics Ltd

Chemomab Therapeutics' Touts Positive Data From Experimental Drug For Chronic Liver Disease

Chemomab's OLE study of nebokitug in PSC patients confirmed safety and showed improvements in liver stiffness, fibrosis biomarkers, and cholestasis markers.

Vandana Singh

Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Avi Kapoor

Chemomab Therapeutics Reveals Data From Mid-Stage Study For Liver Disease Candidate, Stock Plunges On Capital Raise

Chemomab Therapeutics reports successful Phase 2 SPRING trial results for CM-101 in primary sclerosing cholangitis, showing safety and efficacy. Key findings include significant improvements in liver stiffness and pruritis, with a favorable safety profile.

Vandana Singh

What's Going On With Fibro-Inflammatory Disease Focused Chemomab Therapeutics On Tuesday?

Chemomab Therapeutics' CM-101 granted new patents in Brazil and Israel, currently in Phase 2 SPRING trial for primary sclerosing cholangitis. Topline data readout expected by mid-2024.

Vandana Singh

Why M.D.C. Holdings Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket

Shares of M.D.C. Holdings, Inc. (NYSE: MDC) rose sharply in today’s pre-market trading. Sekisui House, Ltd. and M.D.C. Holdings announced an agreement pursuant to which a wholly-owned subsidiary of Sekisui House will acquire MDC in an all-cash deal with an equity value of $4.9 billion.

Avi Kapoor

Finanzas

Trimestral

Anual

Nombre

Ingresos Variación
Bruto Variación
EBITDA Variación
EBIT Variación
Beneficios Variación

Flujos de Caja

Flujo de Caja Operativo (TTM)

-8.73M

Flujo de Caja de Inversión (TTM)

3.22M

Flujo de Caja de Financiación (TTM)

5.91M

Flujo de Caja Libre (TTM)

-8.74M

Gasto de Capital (TTM)

-

Cambio Neto en Efectivo (TTM)

403.00K

Calificación de analistas

4.2

Compra

Compra fuerte

Compra

Mantener

Venta

Venta fuerte

Métricas de Valoración

Valor Empresarial

-$1.10M

Relación P/E (TTM)

-

Relación P/E (FWD)

-

Relación PEG (TTM)

-

Relación P/S (TTM)

-

Relación P/B (TTM)

1.07

Rendimiento de Ganancias % (TTM)

-75.89%

Rendimiento de Ganancias % (FWD)

-

EV / EBITDA (TTM)

-

Precio / EBITDA (TTM)

-

Precio / Flujo de Caja Libre (TTM)

-

Valor Contable / Acción

$1.19

Deuda Empresarial

Deuda Total

-

Deuda a Largo Plazo

-

Emisión de Deuda a Largo Plazo (TTM)

-

Reembolso de Deuda a Largo Plazo (TTM)

-

Efectivo Total

$6.00M

Deuda a Capital

-

Emisión de Deuda (TTM)

-

Reembolso de Deuda (TTM)

-